Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zymeworks Inc.
  6. News
  7. Summary
    ZYME   US98985Y1082

ZYMEWORKS INC.

(ZYME)
  Report
Real-time Estimate Cboe BZX  -  12:22:07 2023-01-30 pm EST
9.510 USD   -0.73%
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Zymeworks Announces Participation in Upcoming Investor Conference

11/22/2022 | 08:35am EST

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:

  • 5th Annual Evercore ISI HealthCONx Conference. Zymeworks’ management will participate in one-on-one meetings on November 29th – December 1st and a fireside chat on November 29th at 4:45 pm Eastern Standard Time (EST).

All presentations and webcasts will be available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.


ę Business Wire 2022
All news about ZYMEWORKS INC.
01/25Zymeworks Announces Participation in Upcoming Investor Conferences
BU
01/20Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phas..
AQ
01/20SVB Securities Raises Price Target on Zymeworks to $10 From $8, Maintains Market Perfor..
MT
01/19Jazz Pharmaceuticals, Zymeworks Announce Positive Results From Phase 2 Trial of Esophag..
MT
01/19Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Pha..
CI
01/12Transcript : Zymeworks Inc. Presents at 41st Annual J.P. Morgan Healthcare Co..
CI
01/04Zymeworks Updates on Cash Resources; Chief Medical Officer to Depart Amid Internal Reor..
MT
01/04Zymeworks Inc. Removes Neil Josephson from the Position of Chief Medical Officer
CI
01/04Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023
BU
01/04HC Wainwright Adjusts Price Target on Zymeworks to $8 From $10, Maintains Neutral Ratin..
MT
More news
Analyst Recommendations on ZYMEWORKS INC.
More recommendations
Financials (USD)
Sales 2022 241 M - -
Net income 2022 6,38 M - -
Net cash 2022 285 M - -
P/E ratio 2022 -38,2x
Yield 2022 -
Capitalization 617 M 617 M -
EV / Sales 2022 1,38x
EV / Sales 2023 5,68x
Nbr of Employees 286
Free-Float 86,5%
Chart ZYMEWORKS INC.
Duration : Period :
Zymeworks Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZYMEWORKS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 9,58 $
Average target price 13,45 $
Spread / Average Target 40,4%
EPS Revisions
Managers and Directors
Kenneth Harry Galbraith Chairman & Chief Executive Officer
Neil A. Klompas Chief Financial Officer
Christopher Astle Chief Financial Officer & Senior Vice President
Paul A. Moore Chief Scientific Officer
Lota S. Zoth Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ZYMEWORKS INC.21.88%617
VERTEX PHARMACEUTICALS11.31%82 513
REGENERON PHARMACEUTICALS, INC.2.96%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008